Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor

Lung adenocarcinoma (LADC) is the most prevalent lung cancer sub-type, and targeted therapy developed in recent years has made progress in its treatment. Erdafitinib, a potent and selective pan-FGFR tyrosine kinase inhibitor, has been confirmed to be effective for the treatment of LADC; however, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Xinmin, Zhu, Xue, Ji, Jiali, Zhong, Hongqin, Li, Xiyue, Zhao, Hongqing, Xie, Guijuan, Wang, Ke, Shu, Hong, Wang, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573074/
https://www.ncbi.nlm.nih.gov/pubmed/36235266
http://dx.doi.org/10.3390/molecules27196733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573074/
https://www.ncbi.nlm.nih.gov/pubmed/36235266
http://dx.doi.org/10.3390/molecules27196733

Ejemplares similares